Investor FAQs

Show all

Investor FAQs

Medidata Solutions is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of our global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations.
Medidata products and services allow customers to achieve clinical results more efficiently and effectively by streamlining the design, planning and management of key aspects of the clinical development process, including protocol development (Medidata Designer™), investigator benchmarking and budgeting (Medidata Grants Manager™), contract research organization (CRO) benchmarking and budgeting (Medidata CRO Contractor™), and the capture, management, analysis and reporting of clinical trial data (Medidata Rave®).
Medidata's diverse customer base spans pharmaceutical, biotechnology and medical device companies, academic institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies.
Medidata Solutions was founded in 1999
The Company's initial public offering (IPO) was on June 25, 2009 at a price of $14.00 per share.
The Company's common stock trades under the stock symbol MDSO.
The Company's shares are listed on NASDAQ Global Market.
Medidata had approximately 59.8 million shares of common stock outstanding as of June 30, 2017.
350 Hudson Street, 9th Floor New York, NY 10014 (212) 918 - 1800
As of June 30, 2017, Medidata Solutions had 1,595 employees and total headcount of over 1,970 including additional non-employee contractors.
The Company's common stock can be purchased or sold through any stock brokerage or discount brokerage firm.
The Company does not offer a direct share purchase plan.
The Company does not issue dividends or have a DRIP program at this time.
You can access the Company's press releases, annual reports, quarterly reports and other materials online at www.mdsol.com.
Our Transfer Agent, American Stock Transfer & Trust Company, can help you in a variety of shareowner-related services including change of address, lost stock certificates, stock transfer, account status and other administrative services. You can write or call our Transfer Agent at:

American Stock Transfer and Trust

Attn: Shareholder Services

6201 15th Avenue

Brooklyn, NY 11219

(888) 257-7340 You may also access our transfer agent over the Internet at http://www.amstock.com. You can check your account balances, access certain shareholder services, and obtain various forms and other helpful information you may need online. Shareowners wishing to transfer their stock should send their written request, stock certificate(s) and other required documentation to:

American Stock Transfer and Trust

Attn: Shareholder Services

6201 15th Avenue

Brooklyn, NY 11219

SEC documents can be accessed under "SEC filings" at www.mdsol.com or at www.sec.gov.
Information regarding the timing of quarterly earnings releases and webcasts is available in the Event Calendar as well as detailed in specific press releases available in the News Section of the corporate Website.
Deloitte & Touche LLP
A copy of the final initial public offering prospectus can be obtained at www.sec.gov.

Stock Split FAQs

No. This is Medidata Solutions’s first stock split
The stock split reflects the Board of Directors' continued confidence in the long-term growth and financial performance of our Company.  A stock split is also expected to make the price of the Company’s stock more affordable and potentially more attractive to new investors
A two-for-one split means that one additional share of stock is issued for each share in existence prior to the split. After the split, each share is worth one-half of what it was worth immediately prior to the split.   Example:
Let’s assume that as of the Record Date (December 2, 2013) an investor owns 100 shares of Medidata Solutions common stock and let’s also assume that the market price of Medidata Solutions stock is $100 per share, so the investment in Medidata Solutions is worth $10,000.  Let’s also assume that the stock price doesn’t move up or down between the record date and the time the split actually takes place.  Immediately after the split, the investor would own 200 shares of Medidata Solutions stock, but the market price would be $50 per share.  The investor’s total investment value in Medidata Solutions would remain the same at $10,000 until the stock price moves up or down.
There are several key dates: The Record Date is on December 2, 2013. This is the date used to determine which stockholders are entitled to receive additional shares due to the split. The Split Date is on December 16, 2013. This is the date when shares issued as a result of the stock split are expected to be distributed by our transfer agent to our stockholders The Ex Date is on December 17, 2013. This is the date on which the trading price of our stock on Nasdaq is adjusted to reflect the split.
We are advised that the issuance of shares in this stock split is not a taxable event for U.S. Federal income tax purposes (under sections 305(a) and 307(a) of the Internal Revenue Code).  The tax basis in each existing share you currently own should be divided equally between that share and the new share received with respect to that share in the stock split, so that following the stock split each share then owned will have a tax basis equal to one-half of the tax basis of a share held prior to the stock split. For example, if you owned 100 shares before the split with a tax basis of $100 per share, after the split you would own 200 shares of stock with a tax basis of $50 per share. We recommend that shareholders consult with their own tax advisor regarding all of the tax consequences resulting from the stock split. Foreign residents should consult their local tax advisors.
No, if you hold a certificate, there is no action that you need to take.  The additional split shares will be added in book entry to a American Stock Transfer and Trust account in your name.  You will receive a statement from American Stock Transfer and Trust reflecting your book-entry holdings which will be sent following the distribution date on December 16, 2013.   You can also access your account on-line at www.amstock.com
If you are a record holder and have questions about the stock split, shareowner records, stock transfers, stock certificates or other stock-related inquiries please contact: American Stock Transfer and Trust Attn: Shareholder Services 6201 15th Avenue Brooklyn, NY 11219 (888) 257-7340 Visit website: www.amstock.com Send email to: info@amstock.com
If your Medidata Solutions shares are held in a brokerage account, they split automatically on the split date. You don’t need to do anything.
When the stock splits on a two-for-one basis, the number of shares outstanding doubles. Earnings per share are one half of what they otherwise would have been as the net earnings are divided by two times as many shares.
No, the stock split will not change your proportionate ownership interest in the Company.
Please click here to view IRS Form 8937

Investor Contact

Betsy Frank
Head of Investor Relations
+1 917 522 4620
bfrank@mdsol.com

Anthony D'Amico
Senior Director, Investor Relations
+1 732 767 4331
adamico@mdsol.com